Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
8
Polynovo Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
stocks
The ASX’s most shorted stocks
stocks
Will CEO departure upend ASX healthcare leader?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,234.30 | 55.70 | -0.60% |
CAC 40 | 7,969.69 | 31.40 | 0.40% |
DAX 40 | 24,363.09 | 69.75 | 0.29% |
Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,339.14 | 234.53 | 0.93% |
NASDAQ | 21,496.54 | 396.22 | 1.88% |
Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
NZX 50 Index | 13,042.76 | 151.31 | -1.15% |
S&P 500 | 6,466.91 | 96.74 | 1.52% |
S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
SSE Composite Index | 3,825.76 | 54.66 | 1.45% |